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Vesicoureteral reflux (VUR) is a common urological 
anomaly that is found in 1% of children. VUR can cause 
recurrent febrile urinary tract infection (UTI). The 
recurrent infections can result in renal scarring, which can 
lead to renal hypertension and end-stage renal disease. Thus, 
our therapeutic goal is to prevent febrile UTI in the short 
term and, in the long term, to preserve renal function by 
inhibiting renal scarring and the associated complications. 
The exact pathophysiology of  VUR and VUR-related 
complications is not yet known. We do not know why 
VUR shows great differences in severity depending on the 
patient. Genetic studies are being conducted on this aspect. 
VUR is a disease that is included in congenital anomalies 
of the kidney and urinary tract (CAKUT). In the article 
“Genetics of vesicoureteral reflux and congenital anomalies 
of the kidney and urinary tract”, Lee et al. [1] summarized 
VUR and CAKUT. CAKUT is a genetically heterogeneous 
group of disorders that are caused by mutations in genes 
involved in the kidney development process. Among the 
genes and signaling pathways, those involved in the 
progression of CAKUT have been evaluated. More than 20 
genes and pathways have been identified that act at each 
step of kidney development. Although it is still too early to 
apply these genetic findings in clinical practice, advances 
in sequencing and bioinformatics technologies illustrate the 
future possibility of early diagnosis, better management, and 
genetic counseling.
Over the past 20 years, changes have taken place con-
cerning how much to evaluate for VUR when febrile 
UTI occurs. Abdelhalim and Khoury [2] organized about 
this in their article, and explained the advantages and 
disadvantages of  the top-down approach, which is the 
most used in Korea. Historically, children with any degree 
of VUR were thought to be at risk of renal damage and 
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underwent surgical correction. On the basis of this concept, 
the American Academy of Pediatrics suggested a bottom-
up approach in 1999 [3]. However, subsequent studies 
have reported that VUR does not always have serious 
consequences and that treatment is not always required 
because spontaneous resolution is common. This has shifted 
the evaluation policy for VUR to a top-down approach that 
relies on a dimercapto-succinic acid (DMSA) renal scan and 
limits the number of voiding cystourethrograms (VCUGs). 
The management has changed because there is no need to 
find VUR without renal damage. Moreover, it is argued 
that there is no clinically meaningful difference in the 
management of  VUR after an acute-stage DMSA scan. 
There are reports that VUR detected by a defect seen on the 
DMSA renal scan is not related to long-term renal scarring. 
This points out a problem of  the top-down approach, in 
addition to the limitations of the DMSA renal scan (economic 
burden, radiation, sedation, and interobserver variability), 
which forms the basis of the top-down approach. As a result, 
the American Academy of Pediatrics in 2011 recommended 
that ultrasonography, although less sensitive than the 
DMSA renal scan, be used detect anatomical abnormalities 
that require further evaluation [4]. However, there is as yet 
no established guideline for VUR diagnosis.
New imaging studies and biomarkers have been inve-
stigated for the diagnosis of  clinically meaningful VUR. 
We have been using ultrasonography, DMSA renal scans, 
and VCUG for decades to diagnose VUR. However, the pain 
and UTI risk of VCUG, poor sensitivity and low positive 
predictive value of ultrasonography, and the aforementioned 
limitations of the DMSA renal scan have yet to be overcome. 
According to Prasad and Cheng [5], there is a movement 
to provide anatomical and functional data in one study 
by using magnetic resonance urography, and interactive 
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magnetic resonance voiding cystography has also been 
attempted. Another recent trend is to diagnose VUR without 
using contrast media or catheterization, as in the case of 
intravoxel incoherent motion diffusion-weighted imaging in 
magnetic resonance imaging [6]. Studies of biomarkers are 
constantly being reported, but it is difficult to find reliable 
markers.
There is as yet no established guideline for the manage-
ment of  VUR diagnosis. Many studies are retro spective, 
heterogeneous, and lack qualified randomized controlled 
studies. Large-scale, prospective, multicenter studies are 
needed to determine whether short-term management of 
febrile UTI can be prevented with various managements 
and whether long-term reductions in renal function can be 
prevented. Studies to date have provided evidence for the 
recurrence of febrile UTI. A typical example is continuous 
antibiotic prophylaxis (CAP). CAP has been around for 
over 40 years, but much controversy remains about its 
effectiveness. Lee and Park [7] revisited the current evidence 
of CAP in their article. Recently, the RIVUR (randomized 
intervention for children with vesicoureteral reflux) trial 
demonstrated that CAP decreased the risk of  recurrent 
UTI in patients with grades I–IV reflux [8]. However, 
evidence is still lacking as to whether renal scarring and the 
reduction in renal function can be prevented. Because CAP 
cannot block renal scarring, there is still a claim that it is 
unnecessary.
However, these treatments cannot be seen to be mea-
ningless owing to the lack of evidence in terms of prevention 
of  renal scarring or renal insufficiency. To assess renal 
scarring and associated renal function, studies should be 
conducted on larger groups of patients for longer periods of 
time than has been done in studies of febrile UTI. It is also 
important to recognize the limitations of the guidelines and 
to recognize that individual cases of VUR may vary.
In the surgical treatment of VUR, endoscopic injection 
therapy (EIT) has grown considerably in the past decade. 
According to Kim et al. [9], despite the excellent short-term 
success rate, increasing reports of  complications such as 
delayed ureteral obstruction and concerns about durability 
limit the use of  EIT. Nevertheless, EIT is a convenient 
method with a single procedure. Further randomized, 
prospective study is required to determine the optimal use 
of EIT in the management of VUR. Laparoscopic surgery 
has been on the rise since the mid-2000s, and robotic surgery 
has been expanding in the 2010s. Although laparoscopic 
surgery is not widely used at present, good results have 
been reported in experienced centers. Robotic surgeries have 
been used more often, but the therapeutic results of these 
surgeries require further validation.
Secondary VUR differs from primary VUR in clinical 
presentation and therapeutic ef fect. Typical cases of 
secondary VUR are posterior urethral valve (PUV) and 
neurogenic bladder. The severe form of PUV is actively 
treated. However, there are various degrees of severity in 
PUV as described by Nakai et al. [10]. The relatively minor 
urethral deformity associated with VUR has not received 
much attention owing to difficulty in understanding its 
clinical manifestations. Urologists need to be constantly 
interested in this, and efforts are needed to diagnose and 
classify these deformities. The presence of VUR in patients 
with neurogenic bladder has a low likelihood of spontaneous 
resolution, and the success rate of  treatment is low. It 
is important to increase the capacity of  the bladder, to 
increase compliance, and to treat the involuntary detrusor 
contraction of  the bladder. Individual bladder dynamic 
evaluation is required, and customized treatment should be 
provided accordingly. In the review done by Wu and Franco 
[11], they emphasized that the surgeon who approaches a 
patient with a neurogenic bladder should always have the 
phrase "Caveat Emptor” in mind since the management 
of VUR in the neurogenic bladder is not as simple as in 
the normal bladder and is fraught with difficulties and 
complications.
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